1. Home
  2. KPRX vs GURE Comparison

KPRX vs GURE Comparison

Compare KPRX & GURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPRX
  • GURE
  • Stock Information
  • Founded
  • KPRX 1998
  • GURE 2006
  • Country
  • KPRX United States
  • GURE China
  • Employees
  • KPRX N/A
  • GURE N/A
  • Industry
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GURE Major Chemicals
  • Sector
  • KPRX Health Care
  • GURE Industrials
  • Exchange
  • KPRX Nasdaq
  • GURE Nasdaq
  • Market Cap
  • KPRX 9.1M
  • GURE 8.5M
  • IPO Year
  • KPRX N/A
  • GURE 1992
  • Fundamental
  • Price
  • KPRX $2.90
  • GURE $0.68
  • Analyst Decision
  • KPRX Strong Buy
  • GURE
  • Analyst Count
  • KPRX 1
  • GURE 0
  • Target Price
  • KPRX $10.00
  • GURE N/A
  • AVG Volume (30 Days)
  • KPRX 1.3M
  • GURE 2.0M
  • Earning Date
  • KPRX 08-08-2025
  • GURE 05-13-2025
  • Dividend Yield
  • KPRX N/A
  • GURE N/A
  • EPS Growth
  • KPRX N/A
  • GURE N/A
  • EPS
  • KPRX N/A
  • GURE N/A
  • Revenue
  • KPRX $20,000.00
  • GURE $7,958,395.00
  • Revenue This Year
  • KPRX N/A
  • GURE N/A
  • Revenue Next Year
  • KPRX N/A
  • GURE N/A
  • P/E Ratio
  • KPRX N/A
  • GURE N/A
  • Revenue Growth
  • KPRX N/A
  • GURE N/A
  • 52 Week Low
  • KPRX $2.51
  • GURE $0.50
  • 52 Week High
  • KPRX $4.86
  • GURE $1.65
  • Technical
  • Relative Strength Index (RSI)
  • KPRX 43.33
  • GURE 50.90
  • Support Level
  • KPRX $2.87
  • GURE $0.66
  • Resistance Level
  • KPRX $3.22
  • GURE $0.99
  • Average True Range (ATR)
  • KPRX 0.18
  • GURE 0.08
  • MACD
  • KPRX -0.02
  • GURE 0.01
  • Stochastic Oscillator
  • KPRX 5.77
  • GURE 29.57

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

About GURE Gulf Resources Inc. (NV)

Gulf Resources Inc is a holding company engaged in the manufacture and trade of bromine and crude salt, and natural gas; manufactures and sells chemical products used in oil and gas field exploration, oil and gas distribution, oil field drilling, wastewater processing, papermaking chemical agents and inorganic chemicals, and manufactures and sells materials for human and animal antibiotics. It operates in four segments: Bromine, Crude Salt, Chemical Products and Natural Gas. It derives maximum revenue from the Bromine segment which is commonly used in brominated flame retardants, fumigants, water purification compounds, dyes, medicines and disinfectants.

Share on Social Networks: